Products - Eye conditions | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 107 products

Date | Title

Ab externo canaloplasty for primary open-angle glaucoma (IPG591)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
13 September 2017
Abicipar pegol for treating wet age-related macular degeneration ID1533
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ab interno canaloplasty for open-angle glaucoma (IPG745)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 November 2022
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 July 2017
AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
15 December 2015
Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care
Status:
Awaiting development
Expected publication date:
TBC
Aflibercept for treating choroidal neovascularisation (TA486)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2017
Aflibercept for treating diabetic macular oedema (TA346)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2014
Aflibercept for untreated diabetic macular oedema [TSID10621]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aflibercept for untreated retinopathy in babies born preterm TS ID 11943
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2013
Age-related macular degeneration (NG82)
Product type:
Guidance
Programme:
NICE guideline
Published:
23 January 2018
AI in retinal scanning MT524 (MIB265)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
AI technologies for detecting diabetic retinopathy (MIB265)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
6 July 2021
Arteriovenous crossing sheathotomy for branch retinal vein occlusion (IPG334)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 March 2010
Artificial iris insertion for acquired aniridia (IPG674)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 July 2020
Artificial iris insertion for congenital aniridia (IPG675)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 July 2020
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 December 2024
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Boston Keratoprosthesis Type I for corneal blindness (MIB91)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
18 January 2017
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Brolucizumab for treating diabetic macular oedema (TA820)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2022
Brolucizumab for treating wet age-related macular degeneration (TA672)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 February 2021
Cataracts in adults: management (NG77)
Product type:
Guidance
Programme:
NICE guideline
Published:
26 October 2017
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Corneal endothelial transplantation (IPG304)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 June 2009
Corneal implants for keratoconus (IPG227)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 July 2007
Corneal implants for the correction of refractive error (IPG225)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 July 2007
Corneal inlay implantation for correction of presbyopia (IPG455)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 April 2013
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2011
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 September 2022
Diabetic retinopathy: management and monitoring (NG242)
Product type:
Guidance
Programme:
NICE guideline
Published:
13 August 2024
Endoscopic dacryocystorhinostomy (IPG113)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2005
Epiretinal brachytherapy for wet age-related macular degeneration (IPG415)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 December 2011
Faricimab for treating diabetic macular oedema (TA799)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 September 2024
Faricimab for treating wet age-related macular degeneration (TA800)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2024
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 July 2019
Glaucoma: diagnosis and management (NG81)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
26 January 2022
Published:
1 November 2017
Glaucoma - lerdelimumab (CAT-152) [ID383]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
High-intensity focused ultrasound for glaucoma (IPG661)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 September 2019
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 August 2017
Icare rebound tonometer to measure intraocular pressure (MIB57)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
15 March 2016
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 September 2025
Implantation of accommodating intraocular lenses for cataract (IPG209)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 February 2007
Implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes (IPG534)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 November 2015
Implantation of an opaque intraocular lens for intractable double vision (IPG293)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 March 2009
Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery (IPG264)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 June 2008
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Insertion of an epiretinal prosthesis for retinitis pigmentosa (IPG519)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 June 2015
Insertion of a subretinal prosthesis system for retinitis pigmentosa (IPG537)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 December 2015
Insertion of hydrogel keratoprosthesis (IPG69)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 June 2004
Intraocular lens insertion for correction of refractive error, with preservation of the natural lens (IPG289)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 February 2009
Laser correction of refractive error following non-refractive ophthalmic surgery (IPG385)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 March 2011
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 October 2024
Lateral orbital decompression
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Limited macular translocation for wet age-related macular degeneration (IPG339)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
19 May 2010
LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
21 April 2015
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macular translocation with 360° retinotomy for wet age-related macular degeneration (IPG340)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
19 May 2010
Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma (IPG612)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 April 2018
Miniature lens system implantation for advanced age-related macular degeneration (IPG565)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 September 2016
Miniature lens system implantation for advanced age-related macular degeneration
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Nerve graft for corneal denervation (IPG729)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
29 June 2022
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
24 April 2018
NVK-002 for treating myopia in people 3 to 17 years [TSID11961]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
ORA G3 to measure corneal hysteresis (MIB150)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
18 June 2018
Pegcetacoplan for treating geographic atrophy [ID4041]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia (IPG466)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 September 2013
Photorefractive (laser) surgery for the correction of refractive errors (IPG164)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 March 2006
Phototherapeutic laser keratectomy for corneal surface irregularities (IPG358)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 September 2010
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 January 2026
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Radiotherapy for age-related macular degeneration (IPG49)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 March 2004
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 May 2024
Published:
27 August 2008
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 May 2024
Published:
27 November 2013
Ranibizumab for treating diabetic macular oedema (TA274)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 October 2023
Published:
27 February 2013
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 May 2024
Published:
22 May 2013
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) (TA941)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2023
Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma (IPG692)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 April 2021
Retrobulbar irradiation for thyroid eye disease (IPG148)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
14 December 2005
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 March 2024
Scleral expansion surgery for presbyopia (IPG70)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2004
Serious eye disorders (QS180)
Product type:
Quality standard
Published:
12 February 2019
TearLab osmolarity system for diagnosing dry eye disease (MIB47)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
15 December 2015
Tebentafusp for treating advanced uveal melanoma (TA1027)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 January 2025
Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) (IPG299)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 May 2009
Teprotumumab for treating thyroid eye disease [ID6432]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 August 2025
The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
19 November 2014
Timrepigene emparvovec for treating choroideremia [ID3916]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium (IPG216)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 April 2007
Trabecular stent bypass microsurgery for open-angle glaucoma (IPG575)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 February 2017
Trabeculectomy with a biodegradable collagen matrix implant for glaucoma (IPG750)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
17 January 2023
Trabeculotomy ab interno for open angle glaucoma (IPG397)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 May 2011
Transpupillary thermotherapy for age-related macular degeneration (IPG58)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 May 2004
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
9 October 2019
YAG laser vitreolysis for symptomatic vitreous floaters (IPG741)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 October 2022